Jpmorgan Chase & CO Altimmune, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Altimmune, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 292,760 shares of ALT stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

292,760

Previous 88,437 231.04%

Holding current value

$1.97 Million

Previous $900,000 116.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$5.91 - $10.23 $1.21 Million - $2.09 Million	204,323 Added 231.04%	292,760 $1.95 Million
Q1 2024 May 10, 2024	SELL	$8.22 - $13.81 $19,382 - $32,563	-2,358 Reduced 2.6%	88,437 $900,000
Q4 2023 Feb 12, 2024	BUY	$2.14 - $11.62 $65,199 - $354,026	30,467 Added 50.5%	90,795 $1.02 Million
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $129,273 - $185,830	-53,864 Reduced 47.17%	60,328 $156,000
Q2 2023 Aug 11, 2023	BUY	$3.45 - $5.97 $131,469 - $227,498	38,107 Added 50.08%	114,192 $403,000
Q1 2023 May 11, 2023	SELL	$4.19 - $16.83 $431,624 - $1.73 Million	-103,013 Reduced 57.52%	76,085 $321,000
Q4 2022 Feb 13, 2023	SELL	$8.74 - $16.45 $4.12 Million - $7.76 Million	-471,930 Reduced 72.49%	179,098 $2.95 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $5.23 Million - $11 Million	490,455 Added 305.44%	651,028 $8.31 Million
Q2 2022 Aug 11, 2022	SELL	$3.94 - $11.77 $579,243 - $1.73 Million	-147,016 Reduced 47.8%	160,573 $1.88 Million
Q1 2022 May 11, 2022	BUY	$5.9 - $9.45 $719,923 - $1.15 Million	122,021 Added 65.76%	307,589 $1.87 Million
Q4 2021 Feb 10, 2022	BUY	$8.69 - $12.48 $1.14 Million - $1.63 Million	130,971 Added 239.89%	185,568 $1.7 Million
Q3 2021 Nov 12, 2021	BUY	$8.43 - $16.81 $460,252 - $917,775	54,597 New	54,597 $617,000

Others Institutions Holding ALT

# of Institutions

189

Shares Held

42.3M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $330M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Altimmune, Inc. Transaction History